RP1 + Nivolumab Rejection: Advocating for Patients and Trust in Clinical Trials
FDA Rejects Promising Melanoma Treatment On July 22, 2025, the Food and Drug Administration (FDA) rejected the approval of a…















Copyright © 2014-2022 - AIM at Melanoma Foundation. All rights reserved. Website by RED ZEPHYR DESIGN